Kadir Çağatay BİÇER, Alpay ARI, Vecdi Evren GENÇ, Sibel ÖZSU CAYMAZ, Meltem AVCI, Fatma BAL

Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients

To evaluate the efficacy of entecavir (ETV) among chronic hepatitis B (CHB) nucleos(t)ide-naïve and -experienced patients in clinical practice. Materials and methods: In this retrospective study 85 CHB patients who had been receiving ETV and who attended our clinic since 2007 were included. Fifty patients were nucleos(t)ide analogue (NA)-naïve. Factors including sex, positive HBeAg, baseline HBV DNA level, baseline alanine aminotransferase level, and prior lamivudine (LAM) resistance were evaluated in terms of their predictive role in treatment response, which was defined as a serum HBV DNA decrease of

Anahtar Kelimeler:

Chronic hepatitis B virus infection, entecavir, efficacy, predictive factors, viral response, lamivudine resistance

Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients

Keywords:

Chronic hepatitis B virus infection, entecavir, efficacy, predictive factors, viral response, lamivudine resistance,

PDF

___

Okita R, Takahashi M, Narahara H, Sanada Y, Okada M, Kawakami Y, Chayama K, Okita K. Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. Clin J Gastroenterol 2009; 2: 214–217.
Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21: 333–337.
Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.
Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493–500.
Bristol-Myers Squibb. Baraclude (Entecavir) Product Monograph, L3 version 1.1. New York, NY, USA: Bristol-Myers Squibb; 2013.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J et al., Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99–108.
Christensen E. Multivariate survival analysis using Cox’s regression model. Hepatology 1987; 7: 1346–1358.
Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198–1209.
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R et al. Entecavir for treatment of lamivudine-refractory, HBeAg- positive chronic hepatitis B. Gastroenterology 2006; 130: 2039–2049.
Sayan M, Hülagü S, Akhan SÇ, Şentürk Ö, Meriç M, Çekmen M. Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients. Mikrobiyol Bul 2009; 43: 425–432 (in Turkish with English abstract).
Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449–454.
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 2012; 57: 508–514.